Hanmi Pharmaceuticals Co Ltd - Company Profile
Powered by 
All the data and insights you need on Hanmi Pharmaceuticals Co Ltd in one report.
$295
- Save hours of research time and resources with
our up-to-date Hanmi Pharmaceuticals Co Ltd Strategy Report
- Understand Hanmi Pharmaceuticals Co Ltd position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Hanmi Pharmaceuticals Catalyst Calendar
Proactively evaluate Hanmi Pharmaceuticals Co Ltd’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.
A sample of Hanmi Pharmaceuticals Catalyst Calendar data
| Event Date | Event Type | Company Name | Ticker Symbol | Drug Name | Therapy Area | Indication | Source Type |
|---|---|---|---|---|---|---|---|
| 01 Dec 2019 | GDCTWXYZ | Lorem | Lorem | Lorem | WXYZ | Planned | Lorem |
| 30 Nov 2019 | Phase III Trial Completion | Hanmi Pharmaceuticals Co Ltd | 128940 | esomeprazole | Gastrointestinal | Reflux Esophagitis (Gastroesophageal Reflux Disease) | Clinical Trial Registry |
| 19 Nov 2019 | Phase II Trial Completion | Hallym University; Hanmi Pharmaceuticals Co Ltd; Kangdong Sacred Heart Hospital | 128940 | (tadalafil + tamsulosin hydrochloride) | Male Health | Benign Prostatic Hyperplasia | Clinical Trial Registry |
| 28 Sep 2019 | Phase I Trial Results | Athenex Inc; Hanmi Pharmaceuticals Co Ltd; PharmaEssentia Corp; Zenith Technology Corporation Ltd | 128940; 6446; ATNX | encequidar mesylate + paclitaxel | Oncology | Solid Tumor; Unspecified Cancer | Company Press Release |
Feature
Catalyst Calendar provides forecasted drug development milestones within the Pharma industry including expected timing, expected outcomes and possible financial impacts.
Benefit
Access:
- Trial Events for trials conducted globally by a company, university, institute or CRO: Trial Initiation, Trial Completion, Trial Results
- Regulatory Events related to drug filings with regulatory bodies, approvals and commercial launches. This is covered for the US, EU and Japan
- Intellectual Property Events for patent and exclusivity expiry specific to the US, EU and Japan: Constraining Patent Expiry (US/EU/Japan), Drug Expiry (US/EU/Japan), Commercial Launch (US/EU/Japan)
Value
Proactively evaluate companies and catalyst impacts
Stay ahead of the competition & improve corporate planning
Bolster business development with timely opportunities
Premium databases is part of our industry range of products
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer